Ultimately, the therapeutic value of EPO in clinical studies in the study population in terms of changes in mortality, arrhythmias’ incidence, thromboembolic events, MACE, LVEF, inflammatory biomarkers, and infarction size have also been discussed. The gene discussed is EPO; the disease is infarction.